Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | May 24, 2017 at 1:55 PM EDT

What to Expect From Eli Lilly at ASCO

24/7 Wall St. takes a look at Eli Lilly, and what Credit Suisse sees happening for this pharma giant at…

Chris Lange | May 24, 2017 at 11:35 AM EDT

Why Inovio Pharmaceuticals May Be the Next Big Thing

Shares of Inovio Pharmaceuticals saw a massive gain early on Wednesday after the company announced a critical update from its…

Chris Lange | May 23, 2017 at 1:40 PM EDT

What Analysts Have to Say About Agilent Technologies After Earnings

After Agilent Technologies reported its quarterly financial results late on Monday, investors were very happy with the beats on both…

Douglas A. McIntyre | May 20, 2017 at 8:05 AM EDT

An STD Test People Can Do at Home

Testing for sexually transmitted diseases has become easier and more discrete as a new company has launched a home test…

Lee Jackson | May 19, 2017 at 8:25 AM EDT

JPMorgan’s Favorite Biotechs to Buy With Massive Upside Potential

After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the…

Chris Lange | May 18, 2017 at 12:30 PM EDT

Why Endologix Shares Are Hitting a Multiyear Low

Endologix saw its shares hit a multiyear low following a meeting with the FDA concerning its Nellix Endovascular Aneurysm Sealing…

Chris Lange | May 18, 2017 at 10:55 AM EDT

How ASCO Could Make or Break These 5 Cancer Drug Trials

The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) has the potential to make or break companies,…

Chris Lange | May 17, 2017 at 12:10 PM EDT

Why This Humira Patent Loss Might Not Be What You Think

AbbVie watched its shares slide on Wednesday following a ruling from the U.S. Patent and Trade Mark Office's Trial and…

Chris Lange | May 17, 2017 at 10:35 AM EDT

Why Syndax Shares Are Rallying

Syndax Pharmaceuticals has announced that Encore 601 has met the prespecified objective response threshold to advance into the second stage…

Jon C. Ogg | May 16, 2017 at 1:40 PM EDT

Is Editas Facing a New Reality in CRISPR Land?

Big opportunities in emerging health care companies often come with very bumpy rides. There is also the risk, of course,…

Chris Lange | May 16, 2017 at 12:20 PM EDT

Why Akebia Shares Are Hitting New Highs

Akebia Therapeutics saw its shares hit a new 52-week high in Tuesday’s session following a key licensing agreement with Vifor…

Chris Lange | May 15, 2017 at 11:58 AM EDT

Did Pantheon Get Enough in Its Buyout?

Pantheon shares saw a huge gain on Monday following the announcement that the company will be acquired by Thermo Fisher…

Paul Ausick | May 15, 2017 at 11:35 AM EDT

Top Credit Suisse Pharma Picks Ahead of Catalysts

Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.

Chris Lange | May 15, 2017 at 10:30 AM EDT

Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results

Ionis Pharmaceuticals saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment…

Chris Lange | May 12, 2017 at 11:50 AM EDT

How Ebola Stocks Are Responding After the Outbreak in the Congo

The WHO has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. A few of…

1 … 166 167 168 169 170 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

What to Expect From Eli Lilly at ASCO

Why Inovio Pharmaceuticals May Be the Next Big Thing

What Analysts Have to Say About Agilent Technologies After Earnings

An STD Test People Can Do at Home

JPMorgan’s Favorite Biotechs to Buy With Massive Upside Potential

Why Endologix Shares Are Hitting a Multiyear Low

How ASCO Could Make or Break These 5 Cancer Drug Trials

Why This Humira Patent Loss Might Not Be What You Think

Why Syndax Shares Are Rallying

Is Editas Facing a New Reality in CRISPR Land?

Why Akebia Shares Are Hitting New Highs

Did Pantheon Get Enough in Its Buyout?

Top Credit Suisse Pharma Picks Ahead of Catalysts

Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results

How Ebola Stocks Are Responding After the Outbreak in the Congo

A $310,000 Portfolio That Pays More Than the Rent on a Big-City East Coast Studio Apartment

Is Jeff Bezos’ New Startup An Even Bigger Idea than Amazon? He Tells CNBC it Will Drive ‘Civilizational Wealth.’

Cramer Calls Intel the “Number One Name” and “More Important Than NVIDIA.” The Stock Soars Today After a Massive Double Upgrade.

A $310,000 Portfolio That Pays More Than the Rent on a Big-City East Coast Studio Apartment

Why Delaying Social Security While Emptying Your 401(k) Can Slash Your Lifetime Taxes

A $310,000 Portfolio That Pays More Than the Rent on a Big-City East Coast Studio Apartment

Is Jeff Bezos’ New Startup An Even Bigger Idea than Amazon? He Tells CNBC it Will Drive ‘Civilizational Wealth.’

Health and Healthcare Articles

All Health and Healthcare Articles

What to Expect From Eli Lilly at ASCO

Why Inovio Pharmaceuticals May Be the Next Big Thing

What Analysts Have to Say About Agilent Technologies After Earnings

An STD Test People Can Do at Home

JPMorgan’s Favorite Biotechs to Buy With Massive Upside Potential

Why Endologix Shares Are Hitting a Multiyear Low

How ASCO Could Make or Break These 5 Cancer Drug Trials

Why This Humira Patent Loss Might Not Be What You Think

Why Syndax Shares Are Rallying

Is Editas Facing a New Reality in CRISPR Land?

Why Akebia Shares Are Hitting New Highs

Did Pantheon Get Enough in Its Buyout?

Top Credit Suisse Pharma Picks Ahead of Catalysts

Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results

How Ebola Stocks Are Responding After the Outbreak in the Congo

A $310,000 Portfolio That Pays More Than the Rent on a Big-City East Coast Studio Apartment

Is Jeff Bezos’ New Startup An Even Bigger Idea than Amazon? He Tells CNBC it Will Drive ‘Civilizational Wealth.’

Cramer Calls Intel the “Number One Name” and “More Important Than NVIDIA.” The Stock Soars Today After a Massive Double Upgrade.

Featured Reads

A $310,000 Portfolio That Pays More Than the Rent on a Big-City East Coast Studio Apartment

Why Delaying Social Security While Emptying Your 401(k) Can Slash Your Lifetime Taxes